MAM
UTHR icon

Martingale Asset Management’s United Therapeutics UTHR Stock Holding History

Martingale Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.13M Buy
7,622
+131
+2% +$73.8K 0.1% 216
2026
Q1 		$4.44M Buy
+7,491
New +$3.73M 0.11% 184
2025
Q3 		– Sell
-15,843
Closed -$4.55M – 847
2025
Q2 		$4.55M Sell
15,843
-955
-6% -$285K 0.11% 159
2025
Q1 		$5.18M Sell
16,798
-17,854
-52% -$6.12M 0.13% 152
2024
Q4 		$12.2M Sell
34,652
-2,450
-7% -$901K 0.3% 112
2024
Q3 		$13.3M Sell
37,102
-5,664
-13% -$1.91M 0.31% 109
2024
Q2 		$13.6M Sell
42,766
-5,537
-11% -$1.47M 0.29% 116
2024
Q1 		$11.1M Sell
48,303
-7,525
-13% -$1.7M 0.22% 131
2023
Q4 		$12.3M Sell
55,828
-250
-0.4% -$57.6K 0.25% 124
2023
Q3 		$12.7M Sell
56,078
-3,990
-7% -$919K 0.27% 119
2023
Q2 		$13.3M Sell
60,068
-2,936
-5% -$650K 0.26% 123
2023
Q1 		$14.1M Buy
63,004
+1,761
+3% +$434K 0.27% 133
2022
Q4 		$17M Sell
61,243
-2,022
-3% -$510K 0.33% 120
2022
Q3 		$13.2M Buy
63,265
+8,140
+15% +$1.82M 0.26% 128
2022
Q2 		$13M Buy
55,125
+6,307
+13% +$1.28M 0.24% 127
2022
Q1 		$8.76M Buy
48,818
+12,434
+34% +$2.37M 0.13% 160
2021
Q4 		$7.86M Buy
36,384
+28,944
+389% +$5.68M 0.1% 168
2021
Q3 		$1.37M Sell
7,440
-81,937
-92% -$16.1M 0.02% 425
2021
Q2 		$16M Sell
89,377
-6,694
-7% -$1.27M 0.18% 154
2021
Q1 		$16.1M Buy
96,071
+30,160
+46% +$5.03M 0.18% 154
2020
Q4 		$10M Buy
65,911
+23,602
+56% +$3.1M 0.11% 177
2020
Q3 		$4.28M Buy
42,309
+27,976
+195% +$3.07M 0.05% 241
2020
Q2 		$1.74M Buy
+14,333
New +$1.61M 0.02% 576
2015
Q4 		– Sell
-1,806
Closed -$238K – 879
2015
Q3 		$238K Hold
1,806
– – 0.01% 782
2015
Q2 		$315K Buy
1,806
+1
+0.1% +$180 0.01% 767
2015
Q1 		$312K Buy
+1,805
New +$275K 0.01% 782
2014
Q4 		– Sell
-1,607
Closed -$207K – 887
2014
Q3 		$207K Buy
+1,607
New +$166K 0.01% 821

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Martingale Asset Management's UTHR Position: Q2 2026 in Review

Martingale Asset Management increased its United Therapeutics (UTHR) stake by 1.7% in Q2 2026, buying an estimated $73.8K and bringing the position to 7,622 shares worth $4.13M. The position accounts for 0.1% of the portfolio, ranked #216.

Martingale Asset Management first reported a position in UTHR in Q3 2014 and has held it in 27 quarters since. The position peaked at $17M in Q4 2022. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Martingale Asset Management held 7,622 shares of United Therapeutics worth $4.13M as of Q2 2026.
  • Martingale Asset Management bought 131 United Therapeutics shares in Q2 2026, an estimated $73.8K.
  • United Therapeutics made up 0.1% of Martingale Asset Management's portfolio in Q2 2026, its #216 holding.
  • Martingale Asset Management first reported a position in United Therapeutics in Q3 2014 and has held it in 27 quarters since.
  • Martingale Asset Management's United Therapeutics position peaked at $17M in Q4 2022.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.